Biosimilar biologics: is the US being left behind?
- Paul Calvo
- World Intellectual Property Review
Paul Calvo authored the article “Biosimilar Biologics: Is the US Being Left Behind?” published in the November/December issue of World Intellectual Property Review. The article discusses the status of biosimilar biologics for the United States and the U.S. Food and Drug Administration (FDA) compared to other agencies worldwide. Calvo states, "Europe continues to forge ahead with approval of increasingly complex biologics, while the US seems to be in a bit of a holding pattern as the final pieces of the regulatory puzzle for biosimilars fall into place."
To read the full article, visit the World Intellectual Property Review website.